An observational study in Ulcerative Colitis, sponsored by Ferring Pharmaceuticals. Completed at 30 sites in Czech Republic. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-07.
Sponsored by Ferring Pharmaceuticals · Observational
Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).
1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.
This study's enrollment of 338 is above the median of 105 across 247 observational studies indexed under Colitis.
Browse Colitis studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients suffering from ulcerative colitis
Exclusion Criteria:
Verify the safety profile
* Number of AEs/SAEs * Intensity and seriousness of reported AEs/SAEs
Time frame: 1 year
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals